AbbVie Inc. Stock
€165.60
Your prediction
Description AbbVie
AbbVie (ABBV) is a publicly listed pharmaceuticals company headquartered in North Chicago, Illinois, United States. It was established in 2013 as a spinoff from Abbott Laboratories, and currently operates in more than 175 countries worldwide. The company has over 47,000 employees and specializes in research, development, and the commercialization of advanced therapies for a variety of diseases, including immunology, oncology, neuroscience, and virology.
ABBV's flagship product is Humira, which is used to treat a range of autoimmune conditions such as rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis. Humira is one of the best-selling prescription drugs globally, generating over $19 billion in 2019.
In addition to Humira, AbbVie also has several other leading drugs in its product portfolio, including Imbruvica, which is used to treat B-cell malignancies like leukemia and lymphoma, and Skyrizi, which is used to treat psoriasis.
ABBV is listed on the New York Stock Exchange (NYSE) under the ticker symbol ABBV, and it is a constituent of the S 500 index. As of 2021, AbbVie has a market capitalization of over $180 billion, making it one of the largest pharmaceutical companies in the world.
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Not a member yet? Sign up for free!
Competitors of AbbVie
AbbVie's most important competitors in the pharmaceutical industry are:
1. Johnson Johnson (Symbol: JNJ)
2. Pfizer Inc. (Symbol: PFE)
3. Merck Co., Inc. (Symbol: MRK)
4. Roche Holding AG (Symbol: RHHBY)
5. Sanofi S.A. (Symbol: SNY)
These companies are all large multinational pharmaceutical companies with strong development pipelines, extensive product portfolios, and substantial global reach. They compete with AbbVie in areas such as immunology, oncology, virology, and neuroscience. In addition, they all have a significant presence in emerging markets, where they are competing to capture market share and grow their businesses. Competition in the pharmaceutical industry is intense, and these companies are continually striving to develop new and innovative drugs to stay ahead of their rivals.
Suppliers of AbbVie
AbbVie is a global biopharmaceutical company that focuses on discovering, developing, and delivering innovative medicines to patients. The company has a number of important suppliers that help it manufacture the drugs it develops, and ensure the quality and safety of its products. Here are some of the most important suppliers of AbbVie:
1. Raw materials suppliers: AbbVie sources raw materials such as chemical compounds, active pharmaceutical ingredients (APIs), excipients, and packaging materials from a wide range of suppliers around the world. These include large chemical and pharmaceutical companies, as well as smaller suppliers specialized in specific raw materials.
2. Contract manufacturers: AbbVie works with a number of contract manufacturers to produce its drugs on a large scale. These manufacturers operate facilities in the United States, Europe, and Asia, and are selected based on their expertise in specific manufacturing processes and their ability to meet AbbVie's quality standards.
3. Equipment and technology suppliers: AbbVie also relies on a variety of suppliers for equipment and technology used in its manufacturing processes. These include providers of specialized laboratory equipment, automated drug manufacturing systems, and software systems for tracking and documenting production processes.
4. Service providers: AbbVie works with a range of service providers to ensure the quality and safety of its products. These include companies that provide testing and analysis of raw materials and finished products, logistics and transportation services, and certification and compliance services.
Overall, AbbVie's suppliers play a critical role in the company's ability to develop and deliver innovative medicines to patients around the world. The company has established strong relationships with these suppliers to ensure the reliability and consistency of its supply chain, and continues to seek out new partners to support its ongoing research and development efforts.
Financial data and news for AbbVie
sharewise wants to provide you with the best news and tools for AbbVie, so we directly link to the best financial data sources.
Financials
News
3 Biotech Giants Gaining From U.S. Sales and Policy Shifts
In today’s unpredictable global trade environment, with rising tariffs and tensions, investors are looking for stability. That means turning to assets that can hold up under pressure, especially
If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy
If you have been or are thinking about getting into AbbVie (NYSE: ABBV), there is still time to do so. The AbbVie stock price is in a sustained uptrend
AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market
AbbVie Inc. (NYSE: ABBV) is trading near an all-time high after the company announced a licensing agreement with Gubra, a Danish company. The agreement
AbbVie Stock: Legal Battle Weighs on Share Price
AbbVie is experiencing a slight downturn in the stock market, with shares currently trading at $209.96, representing a 0.94 percent decline. The pharmaceutical giant's stock dropped by $2.00
AbbVie Stock: $2.1B Cancer Therapy Deal Boosts Portfolio
AbbVie has significantly strengthened its oncology portfolio through a groundbreaking collaboration with Xilio Therapeutics, marking a major expansion into cancer immunotherapy development. The
These Stocks Missed on Earnings, But Will Rebound Next Quarter
Earnings season is when investors get a progress report about the companies in their portfolio or on their watchlist. An earnings report is generally a lagging indicator. That’s because the
AbbVie Investors Trigger Trend-Following Signal: Time to Load Up
AbbVie (NYSE: ABBV) is a high-quality, dividend-growing pharmaceutical company with a robust outlook for growth: now is a good time to load up on shares. Fears of Humira’s patent cliff are
Billionaire Ken Griffin Just Bought More Shares of These Unstoppable Dividend Stocks
Some stock-trading platforms enable their users to automatically replicate the positions taken by experienced investors or other famous figures. Many investors might prefer to do their own research
Don't Fall for These 3 Dividend Stocks: They May Have to Make a Cut.
Dividend stocks can be a smart way to generate steady income, especially in uncertain markets. However, not all dividend payers are created equal. A recent study from Ned Davis Research and Hartford
3 Magnificent Stocks That Are Passive Income Machines
Make money without even trying: That's what passive income is all about. But good investment alternatives are required to make this "easy" money.
Three Motley Fool contributors believe they have
Recession Worries? Here's 1 of the Best Dividend Stocks for Turbulent Times
J.P. Morgan stated last month that it believes there is a 60% chance of a recession in 2025 due to trade wars and tariffs. The raging bull market that started at the beginning of 2023 is in
2 High-Yield Dividend Stocks to Buy in May and Hold Forever
When investing in dividend stocks, paying attention to the right things is essential. A high yield can be attractive, but the most critical factor to consider is a company's underlying operations.
Is the Trump Administration About to Cause AbbVie, Eli Lilly, and Johnson & Johnson Stocks to Crash?
Investors often view Pharmaceutical stocks as safe havens during periods of market turbulence. Stock market volatility or even economic downturns usually don't affect drugmakers' underlying
Why AbbVie Stock Trounced the Market Today
The positive, post-earnings momentum lifting AbbVie's (NYSE: ABBV) stock price continued on Monday. The veteran healthcare company's shares booked a gain of more than 3% during the trading session
Should Investors Be Worried About Dividend King AbbVie?
Nearly everything looked great with AbbVie's (NYSE: ABBV) first-quarter results. The big drugmaker's revenue jumped 8.4% year over year, thanks largely to spectacular growth from autoimmune disease
4 Surefire Dividend Stocks to Buy in the Stock Market Sell-Off
It's always a good time to buy solid dividend stocks, but considering the challenging economic environment, now might be a particularly opportune time. Dividend-paying companies tend to have strong
Why AbbVie Stock Topped the Market Today
A pair of convincing quarterly earnings beats -- not to mention a profitability guidance raise -- made AbbVie (NYSE: ABBV) stock an investor darling on Friday. The pharmaceutical company's
Is AbbVie Stock a Buy?
It's been a stomach-churning past few months for investors in pharmaceutical giant AbbVie (NYSE: ABBV). A potential blockbuster drug that AbbVie spent roughly $9 billion to acquire the rights to
2 Top Dividend Stocks That Could Set You Up for Life
With equity markets in shambles due to President Donald Trump's trade policies, now might be as good a time as any to invest in excellent dividend stocks.
For one, dividend-paying companies tend to
3 Dividend Stocks to Buy and Hold for the Next Decade
What should investors do when stocks are tanking over the short term? Probably the best answer is to think long term.
Three Motley Fool contributors think they've found great dividend stocks to own
Want $1 Million in Retirement? 3 Stocks to Buy Now and Hold for Decades.
Building a retirement portfolio of $1 million or more is within reach for many Americans. The primary things you'll need are time and money to invest.
Do you want $1 million in retirement? There's
2 Dividend Stocks Defying the Market Dip to Buy for a Lifetime of Passive Income
Equities haven't performed well this year due to a combination of factors. Macroeconomic tensions are at the top of that list. Still, some companies are doing just fine amid the volatility
Here's How Many Shares of AbbVie You Need to Own to Get $1,000 in Yearly Dividends
So, you want to invest in AbbVie (NYSE: ABBV) because it's a promising dividend-paying stock, and you also want to receive $1,000 per year in dividend income from it. How many shares should you buy
3 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now
Many investors view the healthcare sector as a safe haven when the stock market is turbulent. That's understandable. The demand for healthcare products and services typically holds up very well
This Top Dividend Stock Just Entered The Weight Loss Market: Is It a Buy?
It's not too often that pharmaceutical drugs become household names, but that's happening with medicines in the weight loss market. Brands such as Wegovy and Zepbound -- the leading anti-obesity